Ernexa Therapeutics Inc.
ERNA
$1.15
-$0.05-4.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.34M | -43.70M | -46.09M | -44.54M | -44.93M |
| Total Depreciation and Amortization | 262.00K | 643.00K | 1.17M | 1.64M | 2.05M |
| Total Amortization of Deferred Charges | 3.11M | 4.34M | 4.81M | 5.26M | 2.40M |
| Total Other Non-Cash Items | 6.98M | 29.28M | 28.69M | 23.78M | 23.61M |
| Change in Net Operating Assets | -1.43M | -4.99M | -2.73M | -1.97M | -80.00K |
| Cash from Operations | -9.41M | -14.43M | -14.15M | -15.84M | -16.95M |
| Capital Expenditure | -22.00K | -19.00K | -268.00K | -369.00K | -388.00K |
| Sale of Property, Plant, and Equipment | 0.00 | 0.00 | 0.00 | 4.00K | 4.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -22.00K | -19.00K | -268.00K | -365.00K | -384.00K |
| Total Debt Issued | 2.25M | 6.14M | 6.14M | 5.29M | 14.58M |
| Total Debt Repaid | -- | -- | -- | -- | -1.50M |
| Issuance of Common Stock | 6.10M | 6.07M | 1.14M | 1.14M | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | 0.00 | -8.00K | -8.00K | -16.00K |
| Other Financing Activities | -135.00K | -135.00K | -149.00K | -169.00K | -110.00K |
| Cash from Financing | 8.22M | 12.08M | 7.13M | 6.26M | 12.95M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.22M | -2.37M | -7.29M | -9.94M | -4.38M |